On November 25, the fourth Ring Road Pharmaceutical (0460.HK) expanded its gains in the afternoon to HK $1.61, or 5.23%, with a total market capitalization of HK $15.22 billion. Xuanzhu Biology, a subsidiary of the group, has received an application from the Drug Review Center of China's State Drug Administration to conduct phase III clinical trials of Pirosini, a class 1 innovative drug, the company announced. The results of preclinical studies show that Pirozinib has unique pharmacokinetic characteristics and can effectively pass through the blood-brain barrier. It is expected to have a good effect on patients with brain metastasis of breast cancer and patients with brain cancer.
港股异动 | 四环医药(0460.HK)涨超5% 轩竹生物吡罗西尼获批开展三期临床试验
Changes in Hong Kong stocks | fourth Ring Pharmaceutical (0460.HK) rose by more than 5%. Pirosini, a bamboo organism, has been approved to carry out phase III clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.